Slashdot: Beta Blockers for Heart Attack Survivors: May Have No Benefit for Most, Could Actually Harm Women
Beta Blockers for Heart Attack Survivors: May Have No Benefit for Most, Could Actually Harm Women
Published on September 01, 2025 at 12:57AM
"A class of drugs called beta-blockers — used for decades as a first-line treatment after a heart attack — doesn't benefit the vast majority of patients," reports CNN. And in fact beta-blockers "may contribute to a higher risk of hospitalization and death in some women but not in men, according to groundbreaking new research..." Women with little heart damage after their heart attacks who were treated with beta-blockers were significantly more likely to have another heart attack or be hospitalized for heart failure — and nearly three times more likely to die — compared with women not given the drug, according to a study published in the European Heart Journal and also scheduled to be presented Saturday at the European Society of Cardiology Congress in Madrid... The findings, however, only applied to women with a left ventricular ejection fraction above 50%, which is considered normal function, the study said. Ejection fraction is a way of measuring how well the left side of the heart is pumping oxygenated blood throughout the body. For anyone with a score below 40% after a heart attack, beta-blockers continue to be the standard of care due to their ability to calm heart arrhythmias that may trigger a second event... The analysis on women was part of a much larger clinical trial called REBOOT — Treatment with Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction — which followed 8,505 men and women treated for heart attacks at 109 hospitals in Spain and Italy for nearly four years. Results of the study were published in Mem>The New England Journal of Medicine and also presented at the European Society of Cardiology Congress. None of the patients in the trial had a left ventricular ejection fraction below 40%, a sign of potential heart failure. "We found no benefit in using beta-blockers for men or women with preserved heart function after heart attack despite this being the standard of care for some 40 years," said Fuster, former editor-in-chief of the Journal of the American College of Cardiology and past president of the American Heart Association and the World Health Federation... In fact, most men and women who survive heart attacks today have ejection fractions above 50%, Ibáñez said [Dr. Borja Ibáñez, scientific director for Madrid's National Center for Cardiovascular Investigation]. "Yet at this time, some 80% of patients in the US, Europe and Asia are treated with beta-blockers because medical guidelines still recommend them...." While the study did not find any need to use beta-blockers for people with a left ventricular ejection fraction above 50% after a heart attack, a separate meta-analysis of 1,885 patients published Saturday in The Lancet did find benefits for those with scores between 40% and 50%, in which the heart may be mildly damaged. "This subgroup did benefit from a routine use of beta-blockers," said Ibáñez, who was also a coauthor on this paper. "We found about a 25% reduction in the primary endpoint, which was a composite of new heart attacks, heart failure and all-cause death."
Published on September 01, 2025 at 12:57AM
"A class of drugs called beta-blockers — used for decades as a first-line treatment after a heart attack — doesn't benefit the vast majority of patients," reports CNN. And in fact beta-blockers "may contribute to a higher risk of hospitalization and death in some women but not in men, according to groundbreaking new research..." Women with little heart damage after their heart attacks who were treated with beta-blockers were significantly more likely to have another heart attack or be hospitalized for heart failure — and nearly three times more likely to die — compared with women not given the drug, according to a study published in the European Heart Journal and also scheduled to be presented Saturday at the European Society of Cardiology Congress in Madrid... The findings, however, only applied to women with a left ventricular ejection fraction above 50%, which is considered normal function, the study said. Ejection fraction is a way of measuring how well the left side of the heart is pumping oxygenated blood throughout the body. For anyone with a score below 40% after a heart attack, beta-blockers continue to be the standard of care due to their ability to calm heart arrhythmias that may trigger a second event... The analysis on women was part of a much larger clinical trial called REBOOT — Treatment with Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction — which followed 8,505 men and women treated for heart attacks at 109 hospitals in Spain and Italy for nearly four years. Results of the study were published in Mem>The New England Journal of Medicine and also presented at the European Society of Cardiology Congress. None of the patients in the trial had a left ventricular ejection fraction below 40%, a sign of potential heart failure. "We found no benefit in using beta-blockers for men or women with preserved heart function after heart attack despite this being the standard of care for some 40 years," said Fuster, former editor-in-chief of the Journal of the American College of Cardiology and past president of the American Heart Association and the World Health Federation... In fact, most men and women who survive heart attacks today have ejection fractions above 50%, Ibáñez said [Dr. Borja Ibáñez, scientific director for Madrid's National Center for Cardiovascular Investigation]. "Yet at this time, some 80% of patients in the US, Europe and Asia are treated with beta-blockers because medical guidelines still recommend them...." While the study did not find any need to use beta-blockers for people with a left ventricular ejection fraction above 50% after a heart attack, a separate meta-analysis of 1,885 patients published Saturday in The Lancet did find benefits for those with scores between 40% and 50%, in which the heart may be mildly damaged. "This subgroup did benefit from a routine use of beta-blockers," said Ibáñez, who was also a coauthor on this paper. "We found about a 25% reduction in the primary endpoint, which was a composite of new heart attacks, heart failure and all-cause death."
Read more of this story at Slashdot.
Comments
Post a Comment